Study design
tumour
TUMOUR
Part B was a multicentre, open-label, multiple-arm, dose-expansion study that evaluated the antitumour activity, safety, and tolerability of pamiparib plus tislelizumab (NCT02660034). The study enrolled patients into eight arms according to tumour type (Supplementary Fig. 